Equities Analysts Offer Predictions for XENE FY2028 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Wedbush dropped their FY2028 earnings per share (EPS) estimates for Xenon Pharmaceuticals in a note issued to investors on Friday, February 28th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will post earnings of $1.22 per share for the year, down from their prior forecast of $1.42. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.05.

A number of other research firms have also commented on XENE. William Blair reiterated an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Friday. Needham & Company LLC restated a “buy” rating and set a $60.00 target price on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Deutsche Bank Aktiengesellschaft assumed coverage on Xenon Pharmaceuticals in a report on Tuesday, February 11th. They set a “buy” rating and a $67.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, Xenon Pharmaceuticals has an average rating of “Buy” and a consensus target price of $57.38.

Xenon Pharmaceuticals Price Performance

XENE opened at $35.79 on Monday. Xenon Pharmaceuticals has a fifty-two week low of $33.27 and a fifty-two week high of $47.80. The firm has a market capitalization of $2.73 billion, a price-to-earnings ratio of -12.69 and a beta of 1.20. The company’s 50 day moving average price is $39.22 and its two-hundred day moving average price is $40.31.

Hedge Funds Weigh In On Xenon Pharmaceuticals

A number of large investors have recently made changes to their positions in XENE. Janus Henderson Group PLC increased its holdings in Xenon Pharmaceuticals by 144.2% during the 3rd quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company’s stock worth $100,506,000 after acquiring an additional 1,507,135 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Xenon Pharmaceuticals by 1,263.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company’s stock worth $38,456,000 after buying an additional 905,129 shares during the last quarter. FMR LLC raised its position in shares of Xenon Pharmaceuticals by 8.8% during the 4th quarter. FMR LLC now owns 7,525,290 shares of the biopharmaceutical company’s stock valued at $294,991,000 after buying an additional 607,606 shares in the last quarter. Boxer Capital Management LLC bought a new stake in shares of Xenon Pharmaceuticals during the 4th quarter worth $23,520,000. Finally, Stempoint Capital LP purchased a new position in Xenon Pharmaceuticals in the fourth quarter worth $14,733,000. 95.45% of the stock is owned by institutional investors.

Insider Activity at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, CFO Sherry Aulin sold 18,709 shares of the business’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total value of $770,997.89. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Ian Mortimer sold 16,315 shares of the stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $40.50, for a total transaction of $660,757.50. Following the transaction, the chief executive officer now owns 31,302 shares of the company’s stock, valued at $1,267,731. This represents a 34.26 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 57,492 shares of company stock valued at $2,334,969 over the last ninety days. Corporate insiders own 5.52% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.